The role of methylprednisolone on preventing disease progression for hospitalized patients with severe COVID-19

被引:21
作者
Yang, Rongrong [1 ]
Xiong, Yong [1 ]
Ke, Hengning [1 ]
Chen, Tielong [1 ]
Gao, Shicheng [1 ]
机构
[1] Wuhan Univ, Zhongnan Hosp, Dept Infect Dis, Donghu Rd 169, Wuhan 430071, Peoples R China
关键词
COVID-19; cytokine storm; methylprednisolone; prognosis; SARS-CoV-2; ACUTE RESPIRATORY SYNDROME; CLINICAL CHARACTERISTICS; CORTICOSTEROID TREATMENT; INFLUENZA; PNEUMONIA; MORTALITY; HYDROCORTISONE;
D O I
10.1111/eci.13412
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background COVID-19 is a public health emergency that is spreading worldwide and seriously affecting the global economy. Data on the effectiveness and safety of the use of methylprednisolone for patients with severe COVID-19 remain limited. Methods In this retrospective study, epidemiological, clinical, laboratory, treatment and outcomes data of hospitalized patients with severe COVID-19 in Zhongnan Hospital of Wuhan University from January 1 to 7 March 2020, were collected. Binary logistic regression model was used to analyse risk factors for disease progression from severe COVID-19 illness to critical illness. The effectiveness and safety of the use of methylprednisolone for patients with severe COVID-19 disease were evaluated. Results The results of the multivariate analysis from 175 patients with severe COVID-19 indicate that the use of methylprednisolone was a protective factor against disease progression from severe to critical illness(P < .001; OR: 0.054 95% CI: 0.017-0.173). Among patients with severe COVID-19 aged < 65 years, both the proportion of patients who progressed to critical illness (42.2% vs 90.0%,P = .000) and the mortality(6.7% vs 30.0%,P = .002) were lower for patients in methylprednisolone group, compared with those in the non-methylprednisolone group, whereas no statistical differences between the methylprednisolone group and the non-methylprednisolone group were found among patients with COVID-19 older than 65 years. Moreover, both the levels of CD4(+)T lymphocyte counts (646 vs 463/mu L,P = .007) and IL-6 (241.9 vs 82.8 pg/mL,P = .025) were higher among patients with severe COVID-19 aged < 65 years, compared with those patients >= 65 years old. Conclusion Data from the limited sample showed that the early use of low or medium doses of methylprednisolone has a positive effect for patients with severe COVID-19 younger than 65 years old, and excessive immune response and cytokine storm may be some of the reasons for the effectiveness.
引用
收藏
页数:8
相关论文
共 34 条
  • [1] Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock
    Annane, D
    Sébille, V
    Charpentier, C
    Bollaert, PE
    François, B
    Korach, JM
    Capellier, G
    Cohen, Y
    Azoulay, E
    Troché, G
    Chaumet-Riffaut, P
    Bellissant, E
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (07): : 862 - 871
  • [2] Corticosteroids for septic shock
    Annane, D
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (07) : S117 - S120
  • [3] Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance
    不详
    [J]. PEDIATRIA I MEDYCYNA RODZINNA-PAEDIATRICS AND FAMILY MEDICINE, 2020, 16 (01): : 9 - 26
  • [4] Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome
    Arabi, Yaseen M.
    Mandourah, Yasser
    Al-Hameed, Fahad
    Sindi, Anees A.
    Almekhlafi, Ghaleb A.
    Hussein, Mohamed A.
    Jose, Jesna
    Pinto, Ruxandra
    Al-Omari, Awad
    Kharaba, Ayman
    Almotairi, Abdullah
    Al Khatib, Kasim
    Alraddadi, Basem
    Shalhoub, Sarah
    Abdulmomen, Ahmed
    Qushmaq, Ismael
    Mady, Ahmed
    Solaiman, Othman
    Al-Aithan, Abdulsalam M.
    Al-Raddadi, Rajaa
    Ragab, Ahmed
    Balkhy, Hanan H.
    Al Harthy, Abdulrahman
    Deeb, Ahmad M.
    Al Mutairi, Hanan
    Al-Dawood, Abdulaziz
    Merson, Laura
    Hayden, Frederick G.
    Fowler, Robert A.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197 (06) : 757 - 767
  • [5] Treatment of severe acute respiratory syndrome with glucosteroids - The Guangzhou experience
    Chen, Rong-chang
    Tang, Xiao-ping
    Tan, Shou-yong
    Liang, Bi-ling
    Wan, Zhuo-yue
    Fang, Ji-qian
    Zhong, Nanshan
    [J]. CHEST, 2006, 129 (06) : 1441 - 1452
  • [6] Clinical Characteristics and Outcomes of Older Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: A Single-Centered, Retrospective Study
    Chen, TieLong
    Dai, Zhe
    Mo, Pingzheng
    Li, Xinyu
    Ma, Zhiyong
    Song, Shihui
    Chen, Xiaoping
    Luo, Mingqi
    Liang, Ke
    Gao, Shicheng
    Zhang, Yongxi
    Deng, Liping
    Xiong, Yong
    [J]. JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2020, 75 (09): : 1788 - 1795
  • [7] Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19
    Fadel, Raef
    Morrison, Austin R.
    Vahia, Amit
    Smith, Zachary R.
    Chaudhry, Zohra
    Bhargava, Pallavi
    Miller, Joseph
    Kenney, Rachel M.
    Alangaden, George
    Ramesh, Mayur S.
    [J]. CLINICAL INFECTIOUS DISEASES, 2020, 71 (16) : 2114 - 2120
  • [8] Guan WJ, 2020, NEW ENGL J MED, V382, P1861, DOI 10.1056/NEJMc2005203
  • [9] Horby P., 2020, NEW ENGL J MED, DOI [DOI 10.1056/NEJMOA2021436, 10.1056/NEJMoa2021436]
  • [10] Effects of corticosteroid and neuraminidase inhibitors on survival in patients with respiratory distress induced by influenza virus
    Huang, Shiang-Fen
    Fung, Chang-Phone
    Perng, Diahn-Warng
    Wang, Fu-Der
    [J]. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2017, 50 (05) : 586 - 594